Jean Brooks
About
Jean Brooks is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery.
According to data from OpenAlex, Jean Brooks has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 2 papers in Surgery. Recurrent topics in Jean Brooks's work include Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Asthma and respiratory diseases (13 papers) and Respiratory Support and Mechanisms (7 papers). Jean Brooks is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Asthma and respiratory diseases (13 papers) and Respiratory Support and Mechanisms (7 papers). Jean Brooks collaborates with scholars based in United States, United Kingdom and South Africa. Jean Brooks's co-authors include Dave Singh, Maggie Tabberer, Sally Kilbride, David Halpin, Mark T. Dransfield, MeiLan K. Han, Nicola C. Day, Frank Barnhart, Fernando J. Martínez and Robert A. Wise and has published in prestigious journals such as New England Journal of Medicine, CHEST Journal and European Respiratory Journal.
In The Last Decade
Jean Brooks
22 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jean Brooks United States | 11 | 1.2k | 936 | 55 | 43 | 42 | 22 | 1.3k | ||
| Frank Barnhart United States | 7 | 1.2k 1.0× | 900 1.0× | 66 1.2× | 56 1.3× | 38 0.9× | 15 | 1.3k | ||
| Noushin Brealey United Kingdom | 13 | 1.3k 1.1× | 964 1.0× | 62 1.1× | 44 1.0× | 36 0.9× | 32 | 1.4k | ||
| Sally Kilbride United States | 14 | 1.6k 1.3× | 1.2k 1.3× | 67 1.2× | 58 1.3× | 49 1.2× | 36 | 1.7k | ||
| Lucy Frith United Kingdom | 10 | 711 0.6× | 570 0.6× | 38 0.7× | 19 0.4× | 21 0.5× | 18 | 815 | ||
| Marcia L. Erbland United States | 10 | 668 0.5× | 375 0.4× | 61 1.1× | 85 2.0× | 34 0.8× | 15 | 877 | ||
| Debora Merrill United States | 11 | 338 0.3× | 162 0.2× | 26 0.5× | 30 0.7× | 69 1.6× | 24 | 493 | ||
| Madlaina Scharplatz Switzerland | 7 | 511 0.4× | 118 0.1× | 18 0.3× | 69 1.6× | 139 3.3× | 7 | 617 | ||
| Michael Koenen‐Bergmann United States | 7 | 354 0.3× | 260 0.3× | 6 0.1× | 19 0.4× | 98 2.3× | 8 | 558 | ||
| Michael Lykens United States | 8 | 192 0.2× | 122 0.1× | 18 0.3× | 30 0.7× | 51 1.2× | 13 | 501 | ||
| Masakazu Hanagama Japan | 9 | 146 0.1× | 100 0.1× | 85 1.5× | 26 0.6× | 16 0.4× | 19 | 292 |
Countries citing papers authored by Jean Brooks
Since
Specialization
Citations
This map shows the geographic impact of Jean Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Brooks more than expected).
Fields of papers citing papers by Jean Brooks
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jean Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Brooks. The network helps show where Jean Brooks may publish in the future.
Co-authorship network of co-authors of Jean Brooks
This figure shows the co-authorship network connecting the top 25 collaborators of Jean Brooks. A scholar is included among the top collaborators of Jean Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Brooks. Jean Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Orchard, Paul J., Robert Wynn, Sandhya Kharbanda, et al.. (2024). Design of a multi-center randomized active controlled phase 3 clinical trial (HURCULES) evaluating the safety and efficacy of OTL-203 in patients with MPS IH versus standard of care with allogeneic hematopoietic stem cell transplantation. Molecular Genetics and Metabolism. 141(2). 107988–107988.
2.
Lipson, David A., Frank Barnhart, Noushin Brealey, et al.. (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine. 378(18). 1671–1680.
3.
Condreay, Lynn D., Lingkang Huang, E Clare Harris, et al.. (2016). Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. Respiratory Medicine. 114. 123–126.
4.
Hoyle, Christopher, et al.. (2016). Mapping the COPD Assessment Test onto EQ-5D. Value in Health. 19(4). 469–477.
5.
Iqbal, Ahmar, Neil Barnes, & Jean Brooks. (2015). Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses. Clinical Drug Investigation. 35(10). 685–688.
6.
Tabberer, Maggie, Jean Brooks, & Teresa K. Wilcox. (2015). A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease. Health and Quality of Life Outcomes. 13(1). 177–177.
7.
Siler, Thomas M., et al.. (2015). Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD Journal of Chronic Obstructive Pulmonary Disease. 13(1). 1–10.
8.
Church, Alison, et al.. (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulmonary Medicine. 14(1). 2–2.
9.
Donohue, James F., Dennis E. Niewoehner, Jean Brooks, Dianne M. O’Dell, & Alison Church. (2014). Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respiratory Research. 15(1). 78–78.
10.
Donohue, James F., Dennis E. Niewoehner, Jean Brooks, Dianne M. O’Dell, & Alison Church. (2013). Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD. European Respiratory Journal. 42(Suppl 57). P760–P760.
11.
Watkins, Michael L., Teresa K. Wilcox, Maggie Tabberer, et al.. (2013). Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open. 3(10). e003048–e003048.
12.
Wilcox, Teresa K., Wen‐Hung Chen, Kellee Howard, et al.. (2013). Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health and Quality of Life Outcomes. 11(1). 196–196.
13.
Donohue, James F., Antonio Anzueto, Jean Brooks, et al.. (2012). A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respiratory Medicine. 106(7). 970–979.
14.
Decramer, Marc, François Maltais, Gregory Feldman, et al.. (2012). Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respiratory Physiology & Neurobiology. 185(2). 393–399.
15.
Bateman, Eric, Gregory Feldman, Sally Kilbride, et al.. (2012). Efficacy and safety of the long‐acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. The Clinical Respiratory Journal. 6(4). 248–257.
16.
Feldman, Gregory, R. Walker, Jean Brooks, Rashmi Mehta, & Glenn Crater. (2012). 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial. Pulmonary Pharmacology & Therapeutics. 25(6). 465–471.
17.
Bateman, Eric, Gregory Feldman, Sally Kilbride, et al.. (2012). Efficacy and safety of the long-acting muscarinic antagonist, GSK233705, delivered once-daily in patients with COPD. The Clinical Respiratory Journal. no–no.
18.
Church, Alison, et al.. (2012). Umeclidinium (GSK573719) dose response and dosing interval in COPD. 40. 2121.
19.
Donohue, James F., Antonio Anzueto, Jean Brooks, et al.. (2011). Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD. CHEST Journal. 140(4). 1043A–1043A.
20.
Singh, Dave, Jean Brooks, Gerry Hagan, Anthony Cahn, & Brian O’Connor. (2008). Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 63(7). 592–598.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Noushin Brealey Breakdown of academic impact, for papers by Sally Kilbride Breakdown of academic impact, for papers by Lucy Frith Breakdown of academic impact, for papers by Marcia L. Erbland Breakdown of academic impact, for papers by Debora Merrill Breakdown of academic impact, for papers by Madlaina Scharplatz Breakdown of academic impact, for papers by Michael Koenen‐Bergmann Breakdown of academic impact, for papers by Michael Lykens Breakdown of academic impact, for papers by Masakazu Hanagama